Alpharma Inc. (ALO) Reports Positive Results
Alpharma Inc. (NYSE:
ALO -
News) reported positive results from its Phase II multi-dose clinical efficacy and pharmacokinetic trial for its abuse-deterrent extended-release opioid. The product allows patients to take pain killers without the possibility of abuse.
This site is not affiliated with Mr. James Cramer, and is not associated with any television networks or broadcasts. Data presented on this site should not be used to make investment decisions and accuracy cannot be guaranteed
GRB Holding Co., LLC
0 Comments:
Post a Comment
<< Home